Addressing a preliminary injunction in patent litigation related to the Biologics Price Competition and Innovation Act (BPCIA), the US Court ...

The U.S. Food and Drug Administration has approved Genentech's Susvimo (ranibizumab) 100 mg/mL for treating diabetic macular ...

EyePoint Pharmaceuticals, Inc. (EYPT) is up by 3.66 percent during Monday trading, rising $0.28 to $7.90. The stock moved higher ...

Shares of EyePoint Pharmaceuticals (NASDAQ:EYPT) rose 10% Wednesday after the company reported positive six-month results from a phase 2 study of its drug Duravyu in the treatment of diabetic macular ...

Despite lackluster sales of Eylea’s high-dose formulation and Sanofi-partnered Dupixent, Regeneron beat Q4 forecasts overall ...

Diabetic Macular Edema MarketThe global diabetic macular edema market is on a steady growth trajectory, with an expected valuation of approximately USD 4,120.9 million in 2024. The market is poised to ...